Literature DB >> 19926406

The use of neuroproteomics in drug abuse research.

Melinda E Lull1, Willard M Freeman, Heather D VanGuilder, Kent E Vrana.   

Abstract

The number of discovery proteomic studies of drug abuse has begun to increase in recent years, facilitated by the adoption of new techniques such as 2D-DIGE and iTRAQ. For these new tools to provide the greatest insight into the neurobiology of addiction, however, it is important that the addiction field has a clear understanding of the strengths, limitations, and drug abuse-specific research factors of neuroproteomic studies. This review outlines approaches for improving animal models, protein sample quality and stability, proteome fractionation, data analysis, and data sharing to maximize the insights gained from neuroproteomic studies of drug abuse. For both the behavioral researcher interested in what proteomic study results mean, and for biochemists joining the drug abuse research field, a careful consideration of these factors is needed. Similar to genomic, transcriptomic, and epigenetic methods, appropriate use of new proteomic technologies offers the potential to provide a novel and global view of the neurobiological changes underlying drug addiction. Proteomic tools may be an enabling technology to identify key proteins involved in drug abuse behaviors, with the ultimate goal of understanding the etiology of drug abuse and identifying targets for the development of therapeutic agents. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19926406      PMCID: PMC3947580          DOI: 10.1016/j.drugalcdep.2009.10.001

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  141 in total

1.  Repeated cocaine administration into the rat ventral tegmental area produces behavioral sensitization to a systemic cocaine challenge.

Authors:  J L Cornish; P W Kalivas
Journal:  Behav Brain Res       Date:  2001-11-29       Impact factor: 3.332

2.  Cocaine abuse elevates alpha-synuclein and dopamine transporter levels in the human striatum.

Authors:  Yujing Qin; Qinjie Ouyang; John Pablo; Deborah C Mash
Journal:  Neuroreport       Date:  2005-09-08       Impact factor: 1.837

Review 3.  Neuroproteomics of the synapse and drug addiction.

Authors:  Noura S Abul-Husn; Lakshmi A Devi
Journal:  J Pharmacol Exp Ther       Date:  2006-04-27       Impact factor: 4.030

4.  Quantitative proteomic profiling of membrane proteins from the mouse brain cortex, hippocampus, and cerebellum using the HysTag reagent: mapping of neurotransmitter receptors and ion channels.

Authors:  Jesper V Olsen; Peter Aa Nielsen; Jens R Andersen; Matthias Mann; Jacek R Wiśniewski
Journal:  Brain Res       Date:  2007-01-17       Impact factor: 3.252

5.  Neurocognitive deficits in cocaine users: a quantitative review of the evidence.

Authors:  Diana Jovanovski; Suzanne Erb; Konstantine K Zakzanis
Journal:  J Clin Exp Neuropsychol       Date:  2005-02       Impact factor: 2.475

6.  Changes in dopamine oxidation currents in the nucleus accumbens during unlimited-access self-administration of d-amphetamine by rats.

Authors:  P. Di Ciano; C.D. Blaha; A.G. Phillips
Journal:  Behav Pharmacol       Date:  1996-11       Impact factor: 2.293

7.  Opiate withdrawal induces dynamic expressions of AMPA receptors and its regulatory molecule CaMKIIalpha in hippocampal synapses.

Authors:  Weixia Zhong; Zhifang Dong; Meng Tian; Jun Cao; Tianle Xu; Lin Xu; Jianhong Luo
Journal:  Life Sci       Date:  2006-03-21       Impact factor: 5.037

Review 8.  Correlating human and animal studies of cocaine abuse and gene expression.

Authors:  Melinda E Lull; Willard M Freeman; Kent E Vrana; Deborah C Mash
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

9.  Cocaine-experienced rats exhibit learning deficits in a task sensitive to orbitofrontal cortex lesions.

Authors:  Geoffrey Schoenbaum; Michael P Saddoris; Seth J Ramus; Yavin Shaham; Barry Setlow
Journal:  Eur J Neurosci       Date:  2004-04       Impact factor: 3.386

10.  Dissection of the insulin signaling pathway via quantitative phosphoproteomics.

Authors:  Marcus Krüger; Irina Kratchmarova; Blagoy Blagoev; Yu-Hua Tseng; C Ronald Kahn; Matthias Mann
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-11       Impact factor: 11.205

View more
  6 in total

Review 1.  Proteomic approaches and identification of novel therapeutic targets for alcoholism.

Authors:  Giorgio Gorini; R Adron Harris; R Dayne Mayfield
Journal:  Neuropsychopharmacology       Date:  2013-07-31       Impact factor: 7.853

Review 2.  Genes and pathways co-associated with the exposure to multiple drugs of abuse, including alcohol, amphetamine/methamphetamine, cocaine, marijuana, morphine, and/or nicotine: a review of proteomics analyses.

Authors:  Ju Wang; Wenji Yuan; Ming D Li
Journal:  Mol Neurobiol       Date:  2011-09-16       Impact factor: 5.590

3.  Gene expression changes in the medial prefrontal cortex and nucleus accumbens following abstinence from cocaine self-administration.

Authors:  Willard M Freeman; Melinda E Lull; Kruti M Patel; Robert M Brucklacher; Drake Morgan; David C S Roberts; Kent E Vrana
Journal:  BMC Neurosci       Date:  2010-02-26       Impact factor: 3.288

4.  The hippocampal neuroproteome with aging and cognitive decline: past progress and future directions.

Authors:  Heather D Vanguilder; Willard M Freeman
Journal:  Front Aging Neurosci       Date:  2011-05-23       Impact factor: 5.750

Review 5.  From Synapse to Function: A Perspective on the Role of Neuroproteomics in Elucidating Mechanisms of Drug Addiction.

Authors:  Luis A Natividad; Matthew W Buczynski; Daniel B McClatchy; John R Yates
Journal:  Proteomes       Date:  2018-12-09

6.  A gold nanoparticle-single-chain fragment variable antibody as an immunoprobe for rapid detection of morphine by dipstick.

Authors:  Sonu Gandhi; Ivneet Banga; Pawan Kumar Maurya; Sergei A Eremin
Journal:  RSC Adv       Date:  2018-01-04       Impact factor: 4.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.